Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions CLL CLL

642. CLL: Therapy, excluding Transplantation I

Watch Session

123 Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, Constantine S. Tam, John N. Allan, et al.

 

124 Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Talha Munir, Rebecca H. Boucher, Nichola Webster, et al.

 

125 Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, Thomas J. Kipps, Barbara Eichhorst, et al.

126 A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter’s Transformation and De Novo Diffuse Large B-Cell Lymphoma

Anthony R. Mato, Stephen J. Schuster, Francine M. Foss, et al.

 

127 Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Othman Al-Sawaf, Can Zhang, Sandra Robrecht, et al.

 

128 Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Shuhua Yi, Jun Du, Ying Yu, et al.